Publication Number: WO/2025/125137
Applicant: GlaxoSmithKline Intellectual Property Development Limited
Filing Date: December 9, 2024 (published mid-2025)
Publication Date: June 19, 2025
What the Patent Covers
This international patent application focuses on antibodies that specifically bind B-cell activating factor (BAFF) — a protein involved in regulation of B cells, a type of immune cell. These BAFF-targeting antibodies are designed to treat autoimmune and inflammatory conditions where BAFF signaling is dysregulated (e.g., systemic lupus erythematosus [SLE], rheumatoid arthritis, Sjögren’s syndrome, certain lymphomas, and other immune-mediated diseases).
In more detail:
- BAFF plays a key role in B-cell survival and maturation; excessive BAFF activity is linked to autoimmunity.
- The claimed antibodies are optimized to selectively recognize human BAFF, neutralizing its interaction with BAFF receptors such as BAFF-R, TACI, and BCMA.
- This therapeutic strategy can modulate B-cell activity and reduce disease-driving autoantibody production.
- GSK’s claims likely include the structure of the antibody molecules, methods for producing them, and methods of use in treating BAFF-mediated diseases.
Why This Patent Is Important
1) Strategic therapeutic relevance:
BAFF-targeting biologics are high-value assets in immunology because they offer novel ways to treat chronic autoimmune diseases with large global patient populations. Successful development and commercialization could significantly boost GSK’s immunology portfolio.
2) Patent positioning:
By securing broad claims around BAFF-specific antibodies, GSK strengthens its intellectual property position ahead of competitive biologics from other major pharma companies. This enhances both R&D leverage and market exclusivity.
3) Revenue potential:
If ultimately developed into approved therapeutics, BAFF-targeted drugs could generate substantial long-term revenues in autoimmune and inflammatory disease markets.
BioTech IP Review 
Leave a comment